Genovate Biotechnology (4130) Stock Overview
Engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4130 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Genovate Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$19.15 |
| 52 Week High | NT$26.40 |
| 52 Week Low | NT$18.50 |
| Beta | 0.26 |
| 1 Month Change | -9.67% |
| 3 Month Change | -5.43% |
| 1 Year Change | -17.47% |
| 3 Year Change | -21.73% |
| 5 Year Change | -49.52% |
| Change since IPO | 2.61% |
Recent News & Updates
Recent updates
Reflecting on Genovate Biotechnology's (GTSM:4130) Share Price Returns Over The Last Five Years
Mar 09
Does It Make Sense To Buy Genovate Biotechnology Co., Ltd. (GTSM:4130) For Its Yield?
Feb 10Genovate Biotechnology Co., Ltd.'s (GTSM:4130) Dismal Stock Performance Reflects Weak Fundamentals
Jan 04
How Much Did Genovate Biotechnology's(GTSM:4130) Shareholders Earn From Share Price Movements Over The Last Five Years?
Dec 08Shareholder Returns
| 4130 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 1.6% | 0.9% | 2.6% |
| 1Y | -17.5% | -8.6% | 0.7% |
Return vs Industry: 4130 underperformed the TW Pharmaceuticals industry which returned -10.3% over the past year.
Return vs Market: 4130 underperformed the TW Market which returned -2.5% over the past year.
Price Volatility
| 4130 volatility | |
|---|---|
| 4130 Average Weekly Movement | 1.8% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 7.9% |
| 10% least volatile stocks in TW Market | 2.5% |
Stable Share Price: 4130 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4130's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 191 | Chia-Chen Chu | www.genovate-bio.com |
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. The company was founded in 1982 and is based in Hsinchu City, Taiwan.
Genovate Biotechnology Co., Ltd. Fundamentals Summary
| 4130 fundamental statistics | |
|---|---|
| Market cap | NT$2.14b |
| Earnings (TTM) | NT$18.61m |
| Revenue (TTM) | NT$502.80m |
Is 4130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4130 income statement (TTM) | |
|---|---|
| Revenue | NT$502.80m |
| Cost of Revenue | NT$318.95m |
| Gross Profit | NT$183.86m |
| Other Expenses | NT$165.25m |
| Earnings | NT$18.61m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.17 |
| Gross Margin | 36.57% |
| Net Profit Margin | 3.70% |
| Debt/Equity Ratio | 0% |
How did 4130 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/18 05:23 |
| End of Day Share Price | 2025/07/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genovate Biotechnology Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li-chun Chang | Jih Sun Securities Investment Consulting Co., Ltd. |
| Xiaowei Huang | Masterlink Securities Corp. |